110 related articles for article (PubMed ID: 19543330)
1. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization.
Tricot G; Cottler-Fox MH; Calandra G
Bone Marrow Transplant; 2010 Jan; 45(1):63-8. PubMed ID: 19543330
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
3. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
4. Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.
Spoerl S; Peter R; Wäscher D; Götze K; Verbeek M; Peschel C; Krackhardt AM
Transfusion; 2017 Jan; 57(1):115-121. PubMed ID: 27859332
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
Stewart DA; Smith C; MacFarland R; Calandra G
Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941
[TBL] [Abstract][Full Text] [Related]
6. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF.
D'Addio A; Curti A; Worel N; Douglas K; Motta MR; Rizzi S; Dan E; Taioli S; Giudice V; Agis H; Kopetzky G; Soutar R; Casadei B; Baccarani M; Lemoli RM
Bone Marrow Transplant; 2011 Mar; 46(3):356-63. PubMed ID: 20577218
[TBL] [Abstract][Full Text] [Related]
7. Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.
Herbert KE; Demosthenous L; Wiesner G; Link E; Westerman DA; Came N; Ritchie DS; Harrison S; Seymour JF; Prince HM
Bone Marrow Transplant; 2014 Aug; 49(8):1056-62. PubMed ID: 24887382
[TBL] [Abstract][Full Text] [Related]
8. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.
Hübel K; Fresen MM; Salwender H; Basara N; Beier R; Theurich S; Christopeit M; Bogner C; Galm O; Hartwig R; Heits F; Lordick F; Rösler W; Wehler D; Zander AR; Albert MH; Dressler S; Ebinger M; Frickhofen N; Hertenstein B; Kiehl M; Liebler S; von Lilienfeld-Toal M; Weidmann E; Weigelt C; Lange F; Kröger N
Bone Marrow Transplant; 2011 Aug; 46(8):1045-52. PubMed ID: 20972470
[TBL] [Abstract][Full Text] [Related]
9. A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor.
Nahi H; Celanovic M; Liu Q; Lund J; Peceliunas V
Biol Blood Marrow Transplant; 2019 Jan; 25(1):34-40. PubMed ID: 30149148
[TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
11. A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure.
Lefrère F; Mauge L; Réa D; Ribeil JA; Dal Cortivo L; Brignier AC; Aoun C; Larghéro J; Cavazzana-Calvo M; Micléa JM
Transfusion; 2013 Mar; 53(3):564-9. PubMed ID: 22725259
[TBL] [Abstract][Full Text] [Related]
12. The effect of mobilizing large numbers of CD34 + cells (super-mobilizers) on the engraftment and survival in patients undergoing autologous stem cell transplantation.
Moreb JS; Lantos L; Chen F; Elliott K; Dugan J; Skarbnik AP; Kropf PL; Ward K
Transfus Apher Sci; 2023 Dec; 62(6):103787. PubMed ID: 37704508
[TBL] [Abstract][Full Text] [Related]
13. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715
[TBL] [Abstract][Full Text] [Related]
14. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation.
Wuchter P; Ran D; Bruckner T; Schmitt T; Witzens-Harig M; Neben K; Goldschmidt H; Ho AD
Biol Blood Marrow Transplant; 2010 Apr; 16(4):490-9. PubMed ID: 19925876
[TBL] [Abstract][Full Text] [Related]
15. Current status of stem cell mobilization.
Gertz MA
Br J Haematol; 2010 Sep; 150(6):647-62. PubMed ID: 20636438
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization.
Sancho JM; Morgades M; Grifols JR; Juncà J; Guardia R; Vives S; Ferrà C; Batlle M; Ester A; Gallardo D; Millà F; Feliu E; Ribera JM
Cytotherapy; 2012 Aug; 14(7):823-9. PubMed ID: 22540329
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma.
Lanza F; Lemoli RM; Olivieri A; Laszlo D; Martino M; Specchia G; Pavone V; Imola M; Pasini A; Milone G; Scortechini I; Todisco E; Guggiari E; Cascavilla N; Martinelli G; Rambaldi A; Bosi A
Transfusion; 2014 Feb; 54(2):331-9. PubMed ID: 23781769
[TBL] [Abstract][Full Text] [Related]
18. Large-volume-apheresis facilitates autologous transplantation of hematopoietic progenitors in poor mobilizer patients.
Majado MJ; Minguela A; González-García C; Salido E; Blanquer M; Funes C; Insausti CL; García-Hernández AM; Moraleda JM; Morales A
J Clin Apher; 2009; 24(1):12-7. PubMed ID: 19170164
[TBL] [Abstract][Full Text] [Related]
19. Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification.
Costa LJ; Nista EJ; Buadi FK; Lacy MQ; Dispenzieri A; Kramer CP; Edwards KH; Kang Y; Gertz MA; Stuart RK; Kumar S
Biol Blood Marrow Transplant; 2014 Feb; 20(2):222-8. PubMed ID: 24211319
[TBL] [Abstract][Full Text] [Related]
20. Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: a simple method using day 1 CD34+ cell yield.
Duong HK; Bolwell BJ; Rybicki L; Koo A; Hsi ED; Figueroa P; Dean R; Pohlman B; Kalaycio M; Andresen S; Sobecks R; Copelan E
J Clin Apher; 2011; 26(3):111-5. PubMed ID: 21647951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
